Результаты поиска

Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.

Both overall survival (OS) and progression-free survival (PFS) are primary endpoints of phase III studies of new anticancer drugs. Medical care expenditures, especially oncology drug prices, are rapidly increasing; however, the impact of oncology drug prices on OS and PFS is unclear. We analyzed the relationship between oncology drug prices and clinical outcomes in Japan. The costs of a full course or 1 year of treatment were estimated on the basis of the latest National Health Insurance Drug Price Standards, and the relationship between costs and improvements in OS or PFS obtained with each d

Совпадение в полном тексте источника
… | Indication | CI OS (¥) Axitinib | RCC | 114 679 | Azacitidine | MDS | 22 687 Afatinib | NSCLC | 29 596 | Abiraterone | PrC | 21 423 Alemtuzumab | CLL | 37 377 | Ipilimumab | MalMel | 66 372 Everolimus | RCC | 50 772 | Eribulin | BC | 23 004 Gefitinib | NSCLC | 19 928 | Erlotinib | NSCLC | 12 240 Sunitinib …

Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class initially designed and approved for treatment of diabetes mellitus, have been shown to exert pleiotropic metabolic and direct cardioprotective and nephroprotective effects that extend beyond their glucose-lowering action. These properties prompted their use in two frequently intertwined conditions, heart failure and chronic kidney disease. Their unique mechanism of action makes SGLT2i an attractive option also to lower the rate of cardiac events and improve overall survival of oncological patients with preexisting cardiovascu

Совпадение в полном тексте источника
… In other preclinical studies, empagliflozin was able to ameliorate cardiomyocyte autophagy induced by sunitinib, an angiogenesis inhibitor. … Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, Beahm C, Chen MH, Force T (2009) Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2:15–25. 10.1111/J.1752-8062.2008.00090.X 64. …

Exploring the Vasculitis-Tumors Link: Epidemiological Patterns, Mechanistic Insights, and Clinical Implications.

This review systematically examines the association between vasculitis and malignancies by summarizing the risk of tumor-associated vasculitis, their clinical characteristics, and proposed pathogenic mechanisms across different vasculitic subtypes. Relevant case reports and mechanistic studies are integrated to provide a comprehensive overview of this entity. The findings offer practical value for rheumatologists in distinguishing primary vasculitis from malignancy-associated forms and optimizing patient surveillance, and for oncologists in improving recognition of tumor-associated vasculitis

Совпадение в полном тексте источника
… Uroscanner: 3 cm hyper‐vascularized mass in the right renal lower pole | Right renal tumorectomy | Complete resolution Massucci et al., 2021 [ 79 ] | LCV | 66 F | Italy | / | / | ANCA negative | Brain MRI: 2‐cm hypodense lesion in the left rolandic area; Total body CT: adrenal metastases | Discontinued sunitinib … Massucci M., Mollica V., Rizzo A., et al., “Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case,” Medicines (Basel) 8, no. 1 (2021): 8010005. 80. Barbu M. …

Effect of the national reimbursement drug list negotiation policy on utilization of negotiated anticancer drugs in Chinese public hospital: a quasi-natural experiment.

BackgroundHigh prices have limited access to targeted anticancer drugs in China. In 2017, 18 such drugs were added to the National Reimbursement Drug List (NRDL) through national price negotiation.MethodMonthly hospital procurement data (2015-2019) from 887 public hospitals across 30 provinces were analyzed. Drug utilization was measured by expenditures and defined daily doses (DDDs). A difference-in-differences (DID) model and interrupted time series (ITS) analysis were employed to estimate policy effects.ResultsFollowing policy implementation, total DDDs of negotiated drugs rose 4.03-fold an

Совпадение в полном тексте источника
… (b) Comparison group: Six similar-targeted anticancer drugs excluded from the negotiation (e.g., Cetuximab, Sunitinib). … ZC02 * | Astragalus polysaccharide for injection | 250 mg (Inj) | Antineoplastic adjuvant drugs | August 2004 ZC02 * | Shenyi capsule | 10 mg (Cap) | Antineoplastic adjuvant drugs | April 2003 Comparison group | L01XC06 ▲ | Cetuximab | 100 mg/20 ml inj | Colorectal cancer | July 2006 | L01XE04 ▲ | Sunitinib …

The Role of Dental Practitioners in the Management of Oncology Patients: The Head and Neck Radiation Oncology Patient and the Medical Oncology Patient.

This narrative review addresses the role of a dentist in the management of oncology patients, highlighting the oral complications that arise in head and neck radiation oncology patients and medical oncology patients. The prevention and management of these complications are discussed.

Совпадение в полном тексте источника
… These antiresorptive medications alongside other oncologic medications, including tyrosine kinase inhibitors (sunitinib and imatinib), monoclonal antibodies (bevacizumab), mTOR inhibitors (everolimus), anti-CTLA4 (ipilimumab), fusion protein (ziv-aflibercept) and immunosuppressants (methotrexate and … Sunitinib related osteonecrosis of jaw: A case report Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2012 113 e1 e3 10.1016/j.tripleo.2011.06.023 22676833 76. Estilo C.L. Fornier M. Farooki A. Carlson D. Bohle G. 3rd Huryn J.M. Osteonecrosis of the jaw related to bevacizumab J. Clin. …

Canine Cancer: Strategies in Experimental Therapeutics.

Cancer is the most common cause of death in adult dogs. Many features of spontaneously developing tumors in pet dogs contribute to their potential utility as a human disease model. These include similar environmental exposures, similar clonal evolution as it applies to important factors such as immune avoidance, a favorable body size for imaging and serial biopsy, and a relatively contracted time course of disease progression, which makes evaluation of temporal endpoints such as progression free or overall survival feasible in a comparatively short time frame. These criteria have been leverage

Совпадение в полном тексте источника
… SU11654 is a structural analog of the human multi-kinase inhibitor sunitinib (Sutent™) with very similar physicochemical properties and IC50's against their intended targets, which include KIT, VEGFR2 and PDGFR-alpha. … These data provided critical information in support of the human development of sunitinib, which is now approved by the U.S. …

Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges.

Gastrointestinal (GI) cancer remains the deadliest cancer in the world. The current standard treatment for GI cancer focuses on 5-fluorouracil-based chemotherapeutic regimens and surgery, and molecular-targeted therapy is expected to be a more effective and less toxic therapeutic strategy for GI cancer. There is well-established evidence for the use of epidermal growth factor receptor-targeted and vascular endothelial growth factor-targeted antibodies, which should routinely be incorporated into treatment strategies for GI cancer. Other potential therapeutic targets involve the PI3K/AKT pathwa

Совпадение в полном тексте источника
… (target VEGFR/PDGFR) | Randomized, open label | Second | II | Completed | Sunitinib + docetaxel NCT01719549 | Dovitinib (target FLT3/c-Kit/ FGFR1/3/VEGFR1/2/3/PDGFR/CFS-1R) | Single group, open label | Third | II | Completed | Dovitinib as a salvage chemotherapy NCT01921673 | Dovitinib | Single group … Similarly, there are several ongoing clinical trials in GI cancer evaluating the use of inhibitors targeting multi-kinases including VEGFR (sunitinib, lenvatinib, nintedanib, dasatinib, carbozantinib, surufatinib, sitravatinib, vorolanib, dovitinib, and telatinib) with or without cytotoxic agents. …

Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches.

The high morbidity and mortality of cancer make it one of the leading causes of global death, thus it is an urgent need to develop effective drugs for cancer therapy. Vascular endothelial growth factor receptor-2 (VEGFR2) acts as a central modulator of angiogenesis, and is therefore an important pharmaceutical target for developing anti-angiogenic agents. In this study, ligand-based naïve Bayesian (NB) models and structure-based molecular docking were combined to develop a virtual screening (VS) pipeline for identifying potential VEGFR2 inhibitors from FDA-approved drugs. The best validated na

Совпадение в полном тексте источника
… steps of angiogenesis including survival, proliferation, migration and capillary-like tube formation of endothelial cells. 6 Therefore, inhibition of VEGFR2 activity emerges as a potential therapy strategy against tumor-induced angiogenesis. 7 Nowadays, several VEGFR2 inhibitors including sorafenib, sunitinib … The performance of the integrated VS pipeline on the FDA-approved antiangiogenic agents Drugbank ID | Drug name | Structure | Company | LibDock Score | Bayesian model (NB-c) EstPGood | Prediction DB00398 | Sorafenib | | Bayer | 148.031 | 1 | True DB01268 | Sunitinib | | Pfizer | 125.116 | 0.978 | True …

Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer.

Pancreatic ductal adenocarcinomas (PDAs) are notoriously aggressive and resistant to treatment. They distinguish themselves further by their robust fibroinflammatory, or desmoplastic, stromal reaction and degree of hypovascularity. Recent findings have revealed multiple mechanisms of stromal complicity in disease pathogenesis and resistance. In this review, we focus on altered physicomechanics as one mechanism of what we term as 'stromal resistance' in PDA. Extremely high interstitial fluid pressures and a dense extracellular matrix combine to limit the delivery and distribution of therapeutic

Совпадение в полном тексте источника
… Science 324 (5933): 1457 –1461 19460966 10.1126/science.1171362 PMC2998180 Olson P, Chu GC, Perry SR, Nolan-Stevaux O, Hanahan D ( 2011 ) Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma . … J 83 (3): 1650 –1660 12202388 10.1016/S0006-3495(02)73933-7 PMC1302261 Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P ( 2011 ) Sunitinib …

Metronomic chemotherapy: changing the paradigm that more is better.

The introduction of the "maximum tolerated dose" in usual treatment protocols (and its concomitant overt toxicity) made necessary the imposition of rest periods between cycles of therapy-a practice that not only involves re-growth of tumour cells, but also growth of selected clones resistant to the therapy. To avoid the problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called "metronomic chemotherapy" has been proposed. This name makes reference to the chronic, equally spaced administration of (generally) low doses of various chemotherapeutic drugs

Совпадение в полном тексте источника
… Blansfield and colleagues 19 administered metronomic cyclophosphamide plus lenalidomide, an immunomodulatory drug, and sunitinib, a tyrosine kinase inhibitor. … Since then, several direct or indirect angiogenesis inhibitors such as bevacizumab, sorafenib, and sunitinib 24 – 27 have been developed, stimulating the proposal of anti-angiogenic therapeutic schedules. …

Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives.

Vascular endothelial growth factor (VEGF) signaling is a critical regulator of vasculogenesis, angiogenesis, and lymphangiogenesis, processes that are vital for the development of vascular and lymphatic systems, tissue repair, and the maintenance of homeostasis. VEGF ligands and their receptors orchestrate endothelial cell proliferation, migration, and survival, playing a pivotal role in dynamic vascular remodeling. Dysregulated VEGF signaling drives diverse pathological conditions, including tumor angiogenesis, cardiovascular diseases, and ocular disorders. Excessive VEGF activity promotes tu

Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer.

PurposeWe previously reported on the pilot study assessing the feasibility of using the Japanese translation of the Comprehensive Score for Financial Toxicity (COST) tool to measure financial toxicity (FT) among Japanese patients with cancer. In this study, we report the results of the prospective survey assessing FT in Japanese patients with cancer using the same tool.Patients and methodsEligible patients were receiving chemotherapy for a solid tumor for at least 2 months. In addition to the COST survey, socioeconomic characteristics were collected by using a questionnaire and medical records

Совпадение в полном тексте источника
… Ninety-six patients (62%) were receiving treatment with at least one molecular targeted agent, including bevacizumab, trastuzumab, cetuximab, panitumumab, ramucirumab, sunitinib, sorafenib, pazopanib, imatinib, lenvatinib, regorafenib, or everolimus. No patients were receiving immunotherapy. …

Acute Respiratory Failure in Patients with Hematologic and Solid Malignancies: Global Approach

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Guillain-Barré Syndrome This syndrome is a form of acute sensorimotor neuropathy that is associated with malignancies like Hodgkin’s lymphoma and chemotherapeutic agents such as vincristine, oxaliplatin, and sunitinib. Lumbar puncture reveals albuminocytologic dissociation. …

Keyword Index for Volume 103

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… single-nucleotide polymorphism) 575 socioeconomic status 136, 303, 446, 741, 1076, 1109, 1496, 1742 sodium selenate 462 soluble interleukin-6 receptor 787 sorafenib 1149, 1637 squamous cell carcinoma 217 squamous cell carcinoma of the head and neck 186 Src kinase 899, 1831 Sri Lanka 303 stroma 1040 sunitinib …

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration (FDA) in 2001, an increasing number of small-molecule targeted drugs have been developed for the treatment of malignancies. By December 2020, 89 small-molecule targeted antitumor drugs have been approved by the US FDA and the National Medical Products Administration (NMPA) of China. Despite great progress, small-mol

Совпадение в полном тексте источника
… The first-generation FLT3 inhibitors, including sorafenib, sunitinib, midostaurin, tandutinib, and lestaurtinib, are multikinase inhibitors. 103 – 105 They are not specific for FLT3 and have inhibitory activity against various other RTKs, such as PDGFR, KIT, VEGFR, RAF, or JAK2. … Among them, sunitinib, an indol-2-one multikinase inhibitor targeting VEGFR-1/2/3, PDGFRα/β, c-Kit, CSF1R, RET, and FLT3, is the second approved anti-angiogenic TKI, and was simultaneously approved for two distinct indications including RCC and imatinib-resistant gastrointestinal stromal tumor (GIST) …

Minimal residual disease in solid tumors: Clinical applications and future directions.

Minimal residual disease (MRD) refers to the presence of residual cancer cells or tumor-derived fragments that persist after treatment and remain undetectable by conventional imaging or protein-based assays. Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for MRD detection. It enables real-time disease monitoring, prognostication, and often therapeutic decision-making. Two major ctDNA approaches exist, tumor-informed and tumor-agnostic, and they differ in sensitivity, specificity, and clinical feasibility. Recent clinical trials have supported a prognostic and predictive utili

Совпадение в полном тексте источника
… tumor evolution through RAS status. 36 , 37 Similarly in advanced gastrointestinal stromal tumor (GIST), ctDNA next‐generation sequencing (NGS) identified imatinib‐resistant mutations missed by tissue testing, enabling personalized second‐line therapy and patients with KIT exons 13/14 benefited from sunitinib … Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 2024;30(2):498‐506. doi: 10.1038/s41591-023-02734-5 39. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. …

Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review.

Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet therapy (DAPT) to patients with cancer who suffer from acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI) is a clinical challenge to cardiologists. Apart from PCI and ACS, other structural interventions, such as TAVR, PFO-ASD closure, and LAA occlusion, and non-cardiac dis

Совпадение в полном тексте источника
… Tyrosine kinase inhibitors (TKIs), such as sorafenib and sunitinib, are both related with hypertension and ACS due to coronary vasospasm because TKIs decrease the vasodilator nitric oxide and increase the vasoconstrictor endothelin-1 [ 31 ]. … acute thrombosis, acceleration of CAD Bevacizumab [ 28 , 36 ] | 0.52–1.7% | ACS, acute thrombosis Leuprolide (GNRH agonist) [ 37 ] | 2.6–5.6% | Angina, ACS, acceleration of CAD Anastrozole (aromatase inhibitor) [ 29 ] | 2% | ACS Tyrosine kinase inhibitors: | | Sorafenib [ 31 ] | 1% | Acute thrombosis Sunitinib …

Antitumoral Agent-Induced Constipation: A Systematic Review.

BackgroundConstipation is a common symptom in patients receiving antitumoral treatment. The mechanisms underlying antitumoral agent-induced constipation (ATAIC) are poorly defined. This systematic review aimed to analyze and synthesize the available information related to the prevalence, etiology, and treatment of ATAIC.MethodsA systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines was conducted. The review included human studies written in English, French, or Spanish involving patients with cancer and containing information abou

Совпадение в полном тексте источника
… moderate: 11%; severe: 4.9% Gay et al., Italy, 2010 [ 28 ] | Narrative review | Thalidomide, melphalan, prednisone, and bortezomib | Multiple myeloma | Not mentioned | Grades 3–4: 4–11% Boussios et al., Greece, 2012 [ 22 ] | Narrative literature review | Oxaliplatin, imatinib, bortezomib, temsirolimus, sunitinib-sorafenib … , and bevacizumab | All cancers | Not mentioned | Oxaliplatin: 32% Imatinib: 4–13% Bortezomib: 43% Temsirolimus: 20% Sunitinib–sorafenib: 34% Bevacizumab: 40% Grenon et al., USA, 2013 [ 23 ] | Narrative review | Bevacizumab, fluorouracil, oxaliplatin, irinotecan, and aflibercept | Metastatic colorectal …

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.

Objective To determine the availability of data on overall survival and quality of life benefits of cancer drugs approved in Europe.Design Retrospective cohort study.Setting Publicly accessible regulatory and scientific reports on cancer approvals by the European Medicines Agency (EMA) from 2009 to 2013.Main outcome measures Pivotal and postmarketing trials of cancer drugs according to their design features (randomisation, crossover, blinding), comparators, and endpoints. Availability and magnitude of benefit on overall survival or quality of life determined at time of approval and after marke

Совпадение в полном тексте источника
… The study was open label 49 Pazopanib (for first line treatment of advanced renal cell carcinoma) significantly improved HRQoL compared with sunitinib with respect to 11 of 14 HRQoL domains. … Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31. 10.1056/NEJMoa1303989. pmid:23964934 . 51. Fizazi K, Scher HI, Molina A, et al. COU-AA-301 Investigators. …

Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.

New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the implementation of effective treatments. Therefore, there is a crucial need for appropriate preclinical models to understand the biological basis of their cardiotoxicity. This scientific statement summarizes the preclinical models hitherto used, from in

Совпадение в полном тексте источника
… Targeting BCR‐ABL with ponatinib causes cardiomyopathy, HF, and vascular occlusion, 13 with mitochondrial toxicity, 14 integrated stress response activation 14 and S100A8/A9‐NLRP3‐interleukin (IL)‐1β‐mediated inflammation 15 identified as key mechanisms in human iPSC and murine models. 14 , 15 Sunitinib … Increased afterload augments sunitinib‐induced cardiotoxicity in an engineered cardiac microtissue model . JACC Basic Transl Sci 2018 ; 3 : 265 – 276 . 10.1016/j.jacbts.2017.12.007 30062212 PMC6059907 17 Xiao L , Salem JE , Clauss S , Hanley A , Bapat A , Hulsmans M , et al . …